The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification

Abstract

The Chinese herbal formula TiaoGanYiPi (TGYP) showed effective against chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) infection. Hence, we aimed to clarify the mechanisms and potential targets between TGYP and CHB. The active compounds and related putative targets of TGYP, and disease targets of CHB were obtained from the public databases. The key targets between TGYP and CHB were identified through the network construction and module analysis. The expression of the key targets was detected in Gene Expression Omnibus (GEO) dataset and normal hepatocyte cell line LO2. We first obtained 11 key targets which were predominantly enriched in the Cancer, Cell cycle and HBV-related pathways. And the expression of the key targets was related to HBV infection and liver inflammation verified in GSE83148 database. Furthermore, the results of real-time quantitative PCR and CCK-8 assay indicated that TGYP could regulate the expression of key targets including CCNA2, ABL1, CDK4, CDKN1A, IGFR and MAP2K1, and promote proliferation of LO2 cells. In coclusion, we identified the active compounds and key targets btween TGYP and CHB, and found that the TGYP might exhibite curative effect on CHB via promoting hepatocyte proliferation and inhibiting the liver inflammatory processes.

Using Network Pharmacology and Molecular Docking to Explore the Mechanism of Qiju Dihuang Pill against Dry Eye Disease

“…If there was no standard SDF format, the Open Babel GUI 3.1.1(http://openbabel.org/wiki/) would be used to convert mol2 format to SDF format [20]. Potential targets related to the active compounds of QJDHP were collected according to the following criteria: the selected species was Homo sapiens, and the probability value was ≥0.1, which was used to measure the accuracy of the current prediction [21].…”

CCL20 and CD8A as potential diagnostic biomarkers for HBV-induced liver fibrosis in chronic hepatitis B

“…Chronic liver disease is one of the major concerns for public health worldwide [ 1 ]. About 2 billion people are infected with HBV around the world, of which 248 million are affected as they test positive for hepatitis B surface antigen (HBsAg).…”

Uncovering the Pharmacological Mechanisms of Gexia-Zhuyu Formula (GXZY) in Treating Liver Cirrhosis by an Integrative Pharmacology Strategy

“…Therefore, it is challenging to study the pharmacological mechanisms of GXZY in the treatment of liver diseases. With the rapid development of bioinformatics, systems biology, and multi-pharmacology, web-based pharmacological methods have a powerful way to explore the compatibility and mechanisms of traditional Chinese medicine prescriptions ( Guo et al, 2019 ; Cao et al, 2021 ). For example, the network pharmacology has been used in the mechanisms of Danggui and safflower in the treatment of blood stasis syndrome ( Yue et al, 2017 ).…”